SCHEMBL17817535

SCHEMBL17817535

CC[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1L1 Q9UHC9 4/20 0.62
▸ CYP2D6 P10635 1/20 0.58
▸ CYP2C19 P33261 1/20 0.58
▸ CDC25A P30304 3/20 0.58
▸ CDC25B P30305 1/20 0.58
▸ INPP5D Q92835 1/20 0.57
▸ PTPN1 P18031 1/20 0.56
▸ SRD5A1 P18405 3/20 0.54
▸ SRD5A2 P31213 3/20 0.54
▸ FNTA P49354 1/20 0.54
▸ FNTB P49356 1/20 0.54
▸ USP2 O75604 3/20 0.53
▸ LMNA P02545 3/20 0.53
▸ IGF1R P08069 1/20 0.53
▸ MET P08581 1/20 0.53
▸ SRC P12931 1/20 0.53
▸ AXL P30530 1/20 0.53
▸ KDR P35968 1/20 0.53
▸ MAP2K1 Q02750 1/20 0.53
▸ PTK2 Q05397 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17817525 1.00 NPC1L1 (0.62) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL9580097 0.91 NPC1L1 (0.60) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL9580104 0.91 NPC1L1 (0.60) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL9580360 0.91 NPC1L1 (0.60) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL9580355 0.91 NPC1L1 (0.60) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL9580391 0.90 NPC1L1 (0.59) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL26642635 0.88 PTPN1 (0.71) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL17817531 0.88 PTPN1 (0.71) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL17817532 0.88 PTPN1 (0.71) NPC1L1CYP2D6CYP2C19CDC25ACDC25B
SCHEMBL26642641 0.88 PTPN1 (0.71) NPC1L1CYP2D6CYP2C19CDC25ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229811-B1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GRI BIO INC (US) 2021-02-24 — — EP disclosed
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 — — WO disclosed
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS ALTIUM GROWTH FUND, LP 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS RXRA, RXRG, CX3CR1 NPC1L1 3549/4885CYP2D6 4407/4885CYP2C19 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback